Skip to main content
Medical information Clinical review pending

Cytogenetics

FISH RET Gene 10q112 Rearrangement Test

The FISH RET Gene 10q112 Rearrangement Test detects specific genetic changes in the RET gene, often linked to certain cancers like thyroid cancer. This test helps guide personalized cancer treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block. The tissue block must contain at least 10% tumor tissue.
Results
Results are typically reported within 4 working days after sample receipt. Confirm with the laboratory before booking.
Preparation
Ensure the Chromosome & FISH analysis Requisition Form (Form 17) is completed and submitted with the sample. Ship the tissue block at room temperature.
Test priceKSh 21,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the FISH RET Gene 10q112 Rearrangement Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients with suspected thyroid cancer
  • ✓Individuals with symptoms suggestive of neuroendocrine tumors
  • ✓Patients with unexplained neck masses or swelling
  • ✓Family history of RET gene-related cancers
  • ✓Monitoring for cancer recurrence or progression
  • ✓Guiding targeted therapy selection
02

In plain language

What this test helps you understand

Detects rearrangements in the RET gene (10q112), which are associated with certain cancers, particularly thyroid cancer and neuroendocrine tumors. Results can help guide personalized treatment strategies and prognosis.
The FISH RET Gene 10q112 Rearrangement Test is a specialized genetic test used in the diagnosis and management of specific cancers. It identifies rearrangements in the RET gene, located on chromosome 10q112. These genetic alterations are frequently associated with various cancers, including thyroid cancer and certain neuroendocrine tumors. Understanding these changes helps doctors tailor treatment plans to individual patient needs.

This test uses Fluorescence In Situ Hybridization (FISH) technology to accurately detect these rearrangements. The information gained from this test is crucial for oncologists in making informed decisions about patient care, potentially improving treatment outcomes.

If you are experiencing symptoms such as unexplained weight loss, persistent cough or hoarseness, swelling in the neck or throat, or changes in bowel or bladder habits, this test might be considered. Individuals with a family history of RET gene-related cancers or those with risk factors for thyroid cancers may also benefit from this testing.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationEnsure the Chromosome & FISH analysis Requisition Form (Form 17) is completed and submitted with the sample. Ship the tissue block at room temperature.
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block. The tissue block must contain at least 10% tumor tissue.
MethodologyFluorescence In Situ Hybridization (FISH)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically detects rearrangements in the RET gene at the 10q112 locus. It does not detect other types of genetic alterations or mutations in other genes. Results must be interpreted in the context of clinical findings and other diagnostic tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This is a genetic test that looks for specific changes (rearrangements) in the RET gene, which can be linked to certain types of cancer, especially thyroid cancer.
It helps doctors diagnose certain cancers, understand the specific type of cancer, and choose the most effective treatment plan for the patient.
A sample of formalin-fixed paraffin-embedded (FFPE) tissue, usually obtained from a biopsy or surgery, is required. The tissue block needs to contain at least 10% tumor cells.
Results are generally available within 4 working days after the laboratory receives the sample. Confirm with the laboratory before booking.
The results will indicate whether the specific RET gene rearrangement was detected. A positive result may influence treatment decisions. Your doctor will explain the results in detail.
No specific patient preparation is required, but ensure the necessary requisition form (Form 17) is completed and submitted with the tissue sample.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp